Skip to Content

Mulpleta Approval History

FDA Approved: Yes (First approved July 31, 2018)
Brand name: Mulpleta
Generic name: lusutrombopag
Dosage form: Tablets
Company: Shionogi Inc.
Treatment for: Thrombocytopenia

Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.

Development History and FDA Approval Process for Mulpleta

DateArticle
Jul 31, 2018Approval FDA Approves Mulpleta (lusutrombopag) for Thrombocytopenia in Adults with Chronic Liver Disease
Feb 27, 2018Shionogi Announces FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) Acceptances for Lusutrombopag (S-888711)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide